OurGLP1 News

GLP-1 developments, explained carefully.

Original summaries of important research, regulation, availability, and safety updates. Every published story links to primary sources and shows its review status clearly.

Primary sourcesFindings, not recommendationsReview status shownNo personalised advice

29 July 2026

Muscle preservation is becoming a new focus in obesity-drug research

A Phase 2 apitegromab study and several registered trials show why obesity-drug research is looking beyond kilograms lost to lean mass, strength and physical function.

Read the sourced summary

29 July 2026

GLP-1 news roundup: Retatrutide Phase 3 results, an oral approval and new eye warnings

A sourced roundup of new Retatrutide Phase 3 results, the US approval of oral orforglipron, Australian NAION warnings and an observational alcohol-hospitalisation study.

Read the sourced summary

How we publish

We report attributed findings, include study or regulatory context, explain uncertainty, distinguish research from approved clinical use, and avoid treatment recommendations.

Read our editorial policy